Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238233 · ClinicalTrials.gov registry record · Phase 4
Wearing-Off Period of Pharmacological Dilation and Anisocoria
A Phase 4 study, sponsored by Prisma Health-Upstate.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT05238233: Completed Phase 4 study, sponsored by Prisma Health-Upstate.
NCT05238233 is a Phase 4 study that has completed, run by Prisma Health-Upstate. The registered enrollment target is 11 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05238233, a Phase 4 study, has completed, sponsored by Prisma Health-Upstate.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
Students at the School of Medicine Greenville will be asked to participate in this study. The aim of this study is to better understand when medical imaging is needed for patients with anisocoria (unequal pupil size). Participation in the study includes up to 3 visits over a period of one week. Each study visit will last about 30 minutes. At the first visit, participants will be screened for hyperopia using a phoropter, have their intraocular pressures taken using a tono-pen, and have their iridocorneal angle measured using gonioscopy at the ophthalmology clinic. Proparacaine hydrochloride 0.5% eye drops will be used to numb the eyes before measuring intraocular pressures and prior to gonio lens exam. Participants will also be asked to complete three forms. Participants will be asked to return to the clinic on a scheduled day within one week of the screening visit to have their left eye dilated. At this visit, the diameter of the pupil will be measured using a Near card in a windowless room with a set light-level. Then, the participant will receive one drop of tropicamide in the left eye. After the drops have had time to take effect, which will be about 20-30 minutes later, the diameter of the pupil will be measured again. Participants will then be asked to return to the clinic in 3-4 hours. At this time, the diameter of the pupil will be measured again. The third type of eye drop used in this study is 1% pilocarpine. 1 % pilocarpine will briefly constrict the eyes. One drop of 1% pilocarpine will be administered to left eye, and the change in pupillary diameter will be measured, if any. It will take about 10-15 minutes for the 1% pilocarpine to take effect. Participants may be required to attend 2 additional 30-minute visits on a third day depending on how their eyes respond to the drops. This study will recruit about 10-15 participants.
Primary Outcome
Measurement of pupil diameter
Interventions
- DRUG Tropicamide
- DRUG 1% Pilocarpine
- DRUG Proparacaine Hydrochloride
- DEVICE Tono pen AVIA
- DEVICE VG4 Gonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2023-01-17 |
| Phase | Phase 4 |
What the finished NCT05238233 record still lists
NCT05238233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which Tropicamide is the first listed.
NCT05238233 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05238233 about?
NCT05238233 is a clinical study titled "Wearing-Off Period of Pharmacological Dilation and Anisocoria". Students at the School of Medicine Greenville will be asked to participate in this study. The aim of this study is to better understand when medical imaging is needed for patients with anisocoria (unequal pupil size). Participation in the study includes up to 3 visits over a period of one week. Ea...
What is the current status of trial NCT05238233?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2022-04-01. Estimated completion is 2023-01-17.
What interventions are being tested in trial NCT05238233?
The interventions under investigation include: Tropicamide (DRUG), 1% Pilocarpine (DRUG), Proparacaine Hydrochloride (DRUG), Tono pen AVIA (DEVICE), VG4 Gonio (DEVICE).
Who is sponsoring clinical trial NCT05238233?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05238233's enrollment target sits among peer trials
11 1931st of 2000 higher than 61 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI